Methotrexate Teva (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting dihydrofolate to tetrahydrofolate. This inhibition reduces the supply of folate cofactors needed for DNA, RNA and protein synthesis, particularly in rapidly dividing cells. The result is decreased proliferation of immune cells and malignant cells, providing therapeutic benefit in autoimmune and oncologic diseases.

The dose of Methotrexate Teva is individualized and set by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Physicians may start with a low dose and adjust gradually, following established clinical guidelines and regular monitoring.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because of a high risk of fetal malformations and miscarriage. It is also not recommended for breastfeeding mothers, as the drug can be excreted in breast milk and may harm the infant.

To order Methotrexate Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

For rheumatoid arthritis, methotrexate is often the first‑line disease‑modifying antirheumatic drug (DMARD) and is less expensive than biologic agents such as TNF‑α inhibitors. In oncology, it offers a distinct mechanism compared with alkylating agents or newer targeted therapies, but may be combined with other drugs for synergistic effect. Choice of therapy depends on disease severity, patient comorbidities and response to prior treatments.

Methotrexate Teva should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If the temperature exceeds the recommended range, discard the product according to local regulations.

Methotrexate Teva is supplied as a sterile injectable solution and may be given by qualified healthcare professionals via epidural, intrabursal or intracoronary routes, depending on the clinical indication. Administration technique, dosage volume and infusion rate are determined by the treating physician and follow institutional protocols.

Serious adverse events include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to anemia or infection, acute renal failure, and life‑threatening allergic reactions. Patients should be monitored regularly for liver enzymes, pulmonary symptoms, renal function and complete blood counts to detect these risks early.

Methotrexate Teva is contraindicated in pregnant women, individuals attempting conception, and those with known hypersensitivity to methotrexate or any component of the formulation. It should also be avoided in patients with severe hepatic impairment, uncontrolled renal failure, or active serious infections unless the benefits clearly outweigh the risks.